{
  "main_header": {
    "sid": 10039711,
    "name": "Star Imaging",
    "stock_name": "Star Imaging",
    "full_name": "Star Imaging and Path Lab Ltd",
    "name_url": "stocks-analysis/star-imaging",
    "exchange": 0,
    "exchangecode": "",
    "country_id": 34,
    "currency": "INR",
    "cmp": "122.00",
    "chg": 1,
    "chgp": "0.83%",
    "dir": 1,
    "prev_price": "121.00",
    "mcapval": "212.52 Cr",
    "mcap": "Micro Cap",
    "scripcode": 544482,
    "symbol": "",
    "ind_name": "Healthcare Services",
    "ind_code": 94,
    "indexname": "",
    "isin": "INE0YG001013",
    "curr_date": "Dec 05",
    "curr_time": "",
    "bse_nse_vol": 2000,
    "exc_status": "Active",
    "traded_date": "Dec 05, 2025",
    "traded_date_str": "2025 12 05",
    "score": "",
    "scoreText": "",
    "Live": 1,
    "market_time": 1,
    "is_blur": 1,
    "is_blur_class": "blur-registerF-score-header",
    "is_blur_url": "https://www.marketsmojo.com/mojofeed/register?redirect=/stocks-analysis/star-imaging-10039711-0&utm_source=Spage_Header_Score",
    "mojoone": {
      "ismore": 0
    }
  },
  "news": {
    "results": [
      {
        "title": "Is Star Imaging overvalued or undervalued?",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/is-star-imaging-overvalued-or-undervalued-3745754",
        "imagepath": "",
        "date": "2025-12-04 08:51:56",
        "description": "    <div class=\"article-news-new\">\n        <div class=\"article-container\">\n\n<div class=\"article-content\">\n\n<p><strong>Valuation Metrics and Financial Performance</strong></p>\n<p>Star Imaging currently trades at a price-to-earnings (PE) ratio of approximately 13.8, which is notably lower than many of its healthcare sector peers. Its price-to-book value stands at 4.66, indicating that the market values the company at nearly five times its net asset value. The enterprise value to EBITDA ratio of 8.67 further suggests a moderate valuation relative to earnings before interest, tax, depreciation, and amortisation. These multiples place Star Imaging in the ‘expensive’ category, a downgrade from its previous ‘very expensive’ status as of early December 2025.</p>\n<p>Importantly, Star Imaging boasts a strong return on capital employed (ROCE) of 31.55% and a return on equity (ROE) of 33.81%, signalling efficient use o..."
      },
      {
        "title": "Is Star Imaging overvalued or undervalued?",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/is-star-imaging-overvalued-or-undervalued-3716840",
        "imagepath": "",
        "date": "2025-11-20 08:08:59",
        "description": "As of 19 November 2025, the valuation grade for Star Imaging has moved from expensive to very expensive, indicating a significant shift in its perceived market value. The company is currently overvalued based on its financial ratios, which include a PE ratio of 14.83, an EV to EBITDA of 9.24, and a ROE of 33.81%. Compared to its peers, Star Imaging's valuation is starkly higher; for instance, Max Healthcare has a PE ratio of 80.06 and Apollo Hospitals stands at 64.09, both of which suggest that Star Imaging is priced at a premium relative to its industry.\n\nIn the context of its recent stock performance, Star Imaging has underperformed the Sensex over the past week with a return of -4.31% compared to the Sensex's 0.85%. This trend reinforces the notion that the company's current valuation may not be justified by its financial performance and market conditions. Overall, Star Imaging's current valuation appear..."
      },
      {
        "title": "How has been the historical performance of Star Imaging?",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/how-has-been-the-historical-performance-of-star-imaging-3699929",
        "imagepath": "",
        "date": "2025-11-13 23:55:54",
        "description": "Answer:\nThe historical performance of Star Imaging shows a significant increase in shareholder's funds and total assets over the past four years, with no standalone results declared. As of March 2025, shareholder's funds reached 47.15 Cr, up from 31.35 Cr in March 2024, and total assets also increased to 98.16 Cr from 81.64 Cr in the previous year. The company has seen a rise in total reserves, which grew to 33.65 Cr in March 2025 from 29.85 Cr in March 2024. Long-term borrowings decreased slightly to 14.87 Cr in March 2025 from 15.71 Cr in March 2024, while short-term borrowings increased to 17.86 Cr from 14.93 Cr in the same period. The profit before tax improved to 21.00 Cr in March 2025, compared to 16.00 Cr in March 2024, indicating a positive trend in profitability.\n\nBreakdown:\nStar Imaging's financial metrics reflect a positive trajectory in its consolidated balance sheet and cash flow results. The c..."
      }
    ],
    "total": 3,
    "sid": "10039711",
    "stock_news_url": "https://www.marketsmojo.com/news/star-imaging-and-path-lab-10039711"
  },
  "announcements": [
    {
      "caption": "Announcement under Regulation 30 (LODR)-Monitoring Agency Report",
      "datetime": "13-Nov-2025",
      "details": "Monitoring Agency Report for the Quarter ended 30th September 2025.",
      "source": "BSE"
    },
    {
      "caption": "Board Meeting Outcome for Unaudited Financial Result (Standalone And Consolidated) For Half Year Ended 30Th September 2025",
      "datetime": "13-Nov-2025",
      "details": "The Board of Directors of the Company at its meeting held today i.e. on Thursday 13 November 2025 has inter alia considered and approved the unaudited (Standalone and Consolidated) financial results of the Company for half year ended 30th September 2025 along with Limited Review Report thereon.",
      "source": "BSE"
    },
    {
      "caption": "Unaudited (Standalone And Consolidated) Financial Results Of The Company For Half Year Ended 30Th September 2025",
      "datetime": "13-Nov-2025",
      "details": "The Board of Directors of the Company at it meeting held today i.e. on Thursday 13 November 2025 has inter alia considered and Approved Unaudited (Standalone and Consolidated) Financial Result for Half year ended 30th September 2025",
      "source": "BSE"
    }
  ],
  "corporate_actions": [
    {
      "img": "board-meeting.svg",
      "title": "BOARD MEETING",
      "msg": "<span>No</span> Upcoming Board Meetings",
      "data": []
    },
    {
      "img": "dividend.svg",
      "title": "DIVIDEND",
      "msg": "No <strong>Dividend</strong> history available",
      "data": []
    },
    {
      "img": "splits.svg",
      "title": "SPLITS",
      "msg": "No <strong>Splits</strong> history available",
      "data": []
    },
    {
      "img": "bonus.svg",
      "title": "BONUS",
      "msg": "No <strong>Bonus</strong> history available",
      "data": []
    },
    {
      "img": "rights-issues.svg",
      "title": "RIGHTS",
      "msg": "No <strong>Rights</strong> history available",
      "data": []
    }
  ]
}

News and Views

Is Star Imaging overvalued or undervalued?

2025-12-04 08:51:56

Valuation Metrics and Financial Performance

Star Imaging currently trades at a price-to-earnings (PE) ratio of approximately 13.8, which is notably lower than many of its healthcare sector peers. Its price-to-book value stands at 4.66, indicating that the market values the company at nearly five times its net asset value. The enterprise value to EBITDA ratio of 8.67 further suggests a moderate valuation relative to earnings before interest, tax, depreciation, and amortisation. These multiples place Star Imaging in the ‘expensive’ category, a downgrade from its previous ‘very expensive’ status as of early December 2025.

Importantly, Star Imaging boasts a strong return on capital employed (ROCE) of 31.55% and a return on equity (ROE) of 33.81%, signalling efficient use o...

Read More

Is Star Imaging overvalued or undervalued?

2025-11-20 08:08:59

As of 19 November 2025, the valuation grade for Star Imaging has moved from expensive to very expensive, indicating a significant shift in its perceived market value. The company is currently overvalued based on its financial ratios, which include a PE ratio of 14.83, an EV to EBITDA of 9.24, and a ROE of 33.81%. Compared to its peers, Star Imaging's valuation is starkly higher; for instance, Max Healthcare has a PE ratio of 80.06 and Apollo Hospitals stands at 64.09, both of which suggest that Star Imaging is priced at a premium relative to its industry. In the context of its recent stock performance, Star Imaging has underperformed the Sensex over the past week with a return of -4.31% compared to the Sensex's 0.85%. This trend reinforces the notion that the company's current valuation may not be justified by its financial performance and market conditions. Overall, Star Imaging's current valuation appear...

Read More

How has been the historical performance of Star Imaging?

2025-11-13 23:55:54

Answer: The historical performance of Star Imaging shows a significant increase in shareholder's funds and total assets over the past four years, with no standalone results declared. As of March 2025, shareholder's funds reached 47.15 Cr, up from 31.35 Cr in March 2024, and total assets also increased to 98.16 Cr from 81.64 Cr in the previous year. The company has seen a rise in total reserves, which grew to 33.65 Cr in March 2025 from 29.85 Cr in March 2024. Long-term borrowings decreased slightly to 14.87 Cr in March 2025 from 15.71 Cr in March 2024, while short-term borrowings increased to 17.86 Cr from 14.93 Cr in the same period. The profit before tax improved to 21.00 Cr in March 2025, compared to 16.00 Cr in March 2024, indicating a positive trend in profitability. Breakdown: Star Imaging's financial metrics reflect a positive trajectory in its consolidated balance sheet and cash flow results. The c...

Read More

View All News